The HSPG2 Knockout SK-HEP-1 Polyclonal Cells product consists of a heterogeneous SK-HEP-1 cell population with CRISPR/Cas9-mediated disruption of the HSPG2 gene, generating a perlecan loss-of-function model. This polyclonal knockout pool avoids clonal selection artifacts while enabling functional studies on collective cell behavior in a relevant hepatic adenocarcinoma background. By targeting perlecan through polyclonal gene disruption, researchers can robustly assess population-level responses without the constraints of monoclonal selection.
SK-HEP-1 is an immortalized human hepatic adenocarcinoma cell line exhibiting both epithelial and endothelial characteristics, widely used to investigate liver cancer biology and endothelial functions. Its endothelial-like phenotype supports studies on angiogenesis, vascular mimicry, and tumor-endothelial interactions. The dual nature of SK-HEP-1 provides a unique platform for exploring the interface between tumor cell plasticity and extracellular matrix-dependent signaling.
Encoded by HSPG2, perlecan is a basement membrane-specific heparan sulfate proteoglycan that binds and presents growth factors such as FGF2, VEGF-A, and PDGF to their cognate receptors, while also anchoring ECM components like laminin, collagen IV, nidogen, and fibronectin. Perlecan engages integrin receptors ITGB1 and ITGAV, activating FAK-Src and downstream MAPK/ERK and PI3K/AKT pathways. Upstream regulators including TGFB1, WNT3A, NFKB1, and HIF1A modulate HSPG2 expression, placing perlecan at a signaling nexus that governs cell adhesion, proliferation, and angiogenesis.
In SK-HEP-1 cells, HSPG2 knockout disrupts basement membrane organization and growth factor sequestration, thereby attenuating FGF2- and VEGF-driven signaling essential for angiogenic and tumorigenic traits. The loss of perlecan impairs integrin-mediated adhesion and reduces cell migration, invasion, and tube formation capacity — key endothelial-like behaviors. This model therefore enables precise dissection of perlecan’s contribution to matrix-guided growth factor presentation and tumor cell plasticity in a hepatic cancer context.
These polyclonal knockout cells serve as a versatile tool for studying liver cancer metastasis, angiogenesis, extracellular matrix remodeling, and growth factor signaling. Compatible assays include Western blotting and RT-qPCR for perlecan verification, immunofluorescence for ECM components, cell adhesion and migration/invasion assessments, tube formation assays, and growth factor binding analyses. Phospho-ERK/AKT profiling and RNA-seq transcriptomics can further elucidate pathway alterations, while drug sensitivity testing can identify perlecan-related vulnerabilities. For further assistance or custom applications, contact Ascent Research.
